Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126870551 | 12687055 | 1 | I | 20160819 | 20160826 | 20160826 | EXP | FR-ROCHE-1817961 | ROCHE | 67.00 | YR | M | Y | 0.00000 | 20160826 | MD | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126870551 | 12687055 | 1 | PS | PEGASYS | PEGINTERFERON ALFA-2A | 1 | Unknown | THERAPY LASTED FOR 3 MONTHS | U | 103964 | |||||||||
| 126870551 | 12687055 | 2 | SS | REBETOL | RIBAVIRIN | 1 | Oral | THERAPY LASTED FOR 3 MONTHS | U | 0 | CAPSULE | ||||||||
| 126870551 | 12687055 | 3 | C | ADVAGRAF | TACROLIMUS | 1 | 0 | ||||||||||||
| 126870551 | 12687055 | 4 | C | IRBESARTAN. | IRBESARTAN | 1 | 0 | ||||||||||||
| 126870551 | 12687055 | 5 | C | AMLODIPINE | AMLODIPINE BESYLATE | 1 | 0 | ||||||||||||
| 126870551 | 12687055 | 6 | C | BISOCE | BISOPROLOL | 1 | 0 | ||||||||||||
| 126870551 | 12687055 | 7 | C | PRAVASTATIN. | PRAVASTATIN | 1 | 0 | ||||||||||||
| 126870551 | 12687055 | 8 | C | KAYEXALATE | SODIUM POLYSTYRENE SULFONATE | 1 | 0 | ||||||||||||
| 126870551 | 12687055 | 9 | C | ALLOPURINOL. | ALLOPURINOL | 1 | Unknown | 0 | |||||||||||
| 126870551 | 12687055 | 10 | C | PREVISCAN (FRANCE) | FLUINDIONE | 1 | 0 | ||||||||||||
| 126870551 | 12687055 | 11 | C | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | 0 | ||||||||||||
| 126870551 | 12687055 | 12 | C | OMEXEL | TAMSULOSIN HYDROCHLORIDE | 1 | 0 | ||||||||||||
| 126870551 | 12687055 | 13 | C | ONEALFA | ALFACALCIDOL | 1 | 0 | ||||||||||||
| 126870551 | 12687055 | 14 | C | OROCAL D3 | CALCIUM CARBONATECHOLECALCIFEROL | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126870551 | 12687055 | 1 | Hepatitis C |
| 126870551 | 12687055 | 2 | Hepatitis C |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126870551 | 12687055 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126870551 | 12687055 | Atrial fibrillation | |
| 126870551 | 12687055 | Renal failure | |
| 126870551 | 12687055 | Therapy non-responder | |
| 126870551 | 12687055 | Thrombotic microangiopathy |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126870551 | 12687055 | 1 | 2007 | 0 | ||
| 126870551 | 12687055 | 2 | 2007 | 0 |